Compare NVTS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVTS | MLYS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2020 | 2023 |
| Metric | NVTS | MLYS |
|---|---|---|
| Price | $9.07 | $23.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $6.68 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 17.6M | 973.7K |
| Earning Date | 05-25-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,916,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $77.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $10.44 |
| 52 Week High | $17.79 | $47.65 |
| Indicator | NVTS | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 48.91 | 29.67 |
| Support Level | $9.03 | $13.42 |
| Resistance Level | $9.23 | $31.09 |
| Average True Range (ATR) | 0.81 | 1.78 |
| MACD | 0.08 | -0.23 |
| Stochastic Oscillator | 32.23 | 3.38 |
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.